MedMira Inc. (MMIRF)
USD 0.02
(-70.43%)
USD 0.02
(-70.43%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 9.27 Million CAD | 11.71% |
| 2022 | 8.29 Million CAD | -28.06% |
| 2021 | 11.53 Million CAD | -3.15% |
| 2020 | 11.91 Million CAD | 38.33% |
| 2019 | 8.61 Million CAD | 13.54% |
| 2018 | 7.58 Million CAD | 9.29% |
| 2017 | 6.93 Million CAD | 11.04% |
| 2016 | 6.24 Million CAD | -10.15% |
| 2015 | 6.95 Million CAD | 11.81% |
| 2014 | 6.22 Million CAD | -9.5% |
| 2013 | 6.87 Million CAD | -7.26% |
| 2012 | 7.41 Million CAD | -49.41% |
| 2011 | 14.65 Million CAD | 14.89% |
| 2010 | 12.75 Million CAD | 8.79% |
| 2009 | 11.72 Million CAD | 9.44% |
| 2008 | 10.71 Million CAD | 4.74% |
| 2007 | 10.22 Million CAD | 8.41% |
| 2006 | 9.43 Million CAD | 15.5% |
| 2005 | 8.16 Million CAD | 76.27% |
| 2004 | 4.63 Million CAD | 141.02% |
| 2003 | 1.92 Million CAD | -79.73% |
| 2002 | 9.48 Million CAD | 25205.64% |
| 2001 | 37.49 Thousand CAD | -99.38% |
| 2000 | 6.03 Million CAD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q3 | 8.85 Million CAD | -0.85% |
| 2024 Q1 | 9.25 Million CAD | -0.14% |
| 2024 Q2 | 8.92 Million CAD | -3.59% |
| 2023 Q2 | 8.88 Million CAD | 2.96% |
| 2023 Q1 | 8.62 Million CAD | 3.97% |
| 2023 FY | 9.27 Million CAD | 11.71% |
| 2023 Q3 | 9.32 Million CAD | 4.93% |
| 2023 Q4 | 9.27 Million CAD | -0.54% |
| 2022 Q3 | 8.35 Million CAD | -0.55% |
| 2022 Q1 | 11.5 Million CAD | -0.29% |
| 2022 FY | 8.29 Million CAD | -28.06% |
| 2022 Q2 | 8.39 Million CAD | -26.97% |
| 2022 Q4 | 8.29 Million CAD | -0.65% |
| 2021 Q4 | 11.53 Million CAD | 0.2% |
| 2021 Q1 | 11.82 Million CAD | -0.68% |
| 2021 Q2 | 11.72 Million CAD | -0.84% |
| 2021 FY | 11.53 Million CAD | -3.15% |
| 2021 Q3 | 11.51 Million CAD | -1.85% |
| 2020 Q4 | 11.91 Million CAD | -0.41% |
| 2020 Q1 | 11.28 Million CAD | 31.05% |
| 2020 Q2 | 11.82 Million CAD | 4.76% |
| 2020 Q3 | 11.95 Million CAD | 1.18% |
| 2020 FY | 11.91 Million CAD | 38.33% |
| 2019 Q4 | 8.61 Million CAD | 4.37% |
| 2019 Q1 | 7.97 Million CAD | 5.22% |
| 2019 FY | 8.61 Million CAD | 13.54% |
| 2019 Q2 | 8.19 Million CAD | 2.75% |
| 2019 Q3 | 8.24 Million CAD | 0.62% |
| 2018 Q3 | 7.53 Million CAD | 1.73% |
| 2018 Q4 | 7.58 Million CAD | 0.59% |
| 2018 FY | 7.58 Million CAD | 9.29% |
| 2018 Q1 | 7.31 Million CAD | 5.48% |
| 2018 Q2 | 7.41 Million CAD | 1.26% |
| 2017 Q1 | 6.26 Million CAD | 0.21% |
| 2017 Q4 | 6.93 Million CAD | 4.48% |
| 2017 Q3 | 6.64 Million CAD | 6.36% |
| 2017 Q2 | 6.24 Million CAD | -0.29% |
| 2017 FY | 6.93 Million CAD | 11.04% |
| 2016 FY | 6.24 Million CAD | -10.15% |
| 2016 Q4 | 6.24 Million CAD | 4.65% |
| 2016 Q1 | 6.45 Million CAD | -7.17% |
| 2016 Q3 | 5.97 Million CAD | -2.89% |
| 2016 Q2 | 6.14 Million CAD | -4.76% |
| 2015 Q4 | 6.95 Million CAD | 12.59% |
| 2015 FY | 6.95 Million CAD | 11.81% |
| 2015 Q2 | 6.63 Million CAD | 3.47% |
| 2015 Q1 | 6.4 Million CAD | 3.04% |
| 2015 Q3 | 6.17 Million CAD | -6.85% |
| 2014 FY | 6.22 Million CAD | -9.5% |
| 2014 Q4 | 6.22 Million CAD | 7.59% |
| 2014 Q3 | 5.78 Million CAD | -5.45% |
| 2014 Q2 | 6.11 Million CAD | -3.45% |
| 2014 Q1 | 6.33 Million CAD | -7.86% |
| 2013 Q1 | 7.81 Million CAD | 5.44% |
| 2013 FY | 6.87 Million CAD | -7.26% |
| 2013 Q4 | 6.87 Million CAD | 9.28% |
| 2013 Q3 | 6.29 Million CAD | 3.71% |
| 2013 Q2 | 6.06 Million CAD | -22.4% |
| 2012 Q3 | 17.01 Million CAD | -0.48% |
| 2012 Q2 | 17.1 Million CAD | 17.86% |
| 2012 Q1 | 14.5 Million CAD | -0.99% |
| 2012 FY | 7.41 Million CAD | -49.41% |
| 2012 Q4 | 7.41 Million CAD | -56.44% |
| 2011 Q3 | 14.71 Million CAD | 1.05% |
| 2011 Q1 | 13.32 Million CAD | 4.51% |
| 2011 FY | 14.65 Million CAD | 14.89% |
| 2011 Q4 | 14.65 Million CAD | -0.42% |
| 2011 Q2 | 14.56 Million CAD | 9.25% |
| 2010 Q1 | 6.81 Million CAD | -41.87% |
| 2010 Q2 | 9.38 Million CAD | 37.75% |
| 2010 Q3 | 11.93 Million CAD | 27.2% |
| 2010 Q4 | 12.75 Million CAD | 6.82% |
| 2010 FY | 12.75 Million CAD | 8.79% |
| 2009 Q3 | 11.87 Million CAD | -2.4% |
| 2009 FY | 11.72 Million CAD | 9.44% |
| 2009 Q1 | 11.22 Million CAD | 4.81% |
| 2009 Q2 | 12.16 Million CAD | 8.33% |
| 2009 Q4 | 11.72 Million CAD | -1.25% |
| 2008 Q4 | 10.71 Million CAD | 7.05% |
| 2008 FY | 10.71 Million CAD | 4.74% |
| 2008 Q3 | 10 Million CAD | -2.12% |
| 2008 Q2 | 10.22 Million CAD | 4.91% |
| 2008 Q1 | 9.74 Million CAD | -4.71% |
| 2007 Q3 | 10.56 Million CAD | 0.06% |
| 2007 FY | 10.22 Million CAD | 8.41% |
| 2007 Q2 | 10.56 Million CAD | -51.64% |
| 2007 Q4 | 10.22 Million CAD | -3.23% |
| 2007 Q1 | 21.84 Million CAD | 131.49% |
| 2006 Q3 | 8.26 Million CAD | -25.86% |
| 2006 Q4 | 9.43 Million CAD | 14.21% |
| 2006 FY | 9.43 Million CAD | 15.5% |
| 2006 Q1 | 10.59 Million CAD | 29.71% |
| 2006 Q2 | 11.14 Million CAD | 5.16% |
| 2005 Q1 | 6.36 Million CAD | 37.35% |
| 2005 FY | 8.16 Million CAD | 76.27% |
| 2005 Q3 | 7.05 Million CAD | 5.4% |
| 2005 Q4 | 8.16 Million CAD | 15.86% |
| 2005 Q2 | 6.68 Million CAD | 5.09% |
| 2004 FY | 4.63 Million CAD | 141.02% |
| 2004 Q1 | 2 Million CAD | 4.16% |
| 2004 Q4 | 4.63 Million CAD | 35.35% |
| 2004 Q2 | 2.29 Million CAD | 14.36% |
| 2004 Q3 | 3.42 Million CAD | 49.49% |
| 2003 Q4 | 1.92 Million CAD | -79.79% |
| 2003 FY | 1.92 Million CAD | -79.73% |
| 2003 Q1 | 9.53 Million CAD | 0.54% |
| 2003 Q2 | 9.07 Million CAD | -4.83% |
| 2003 Q3 | 9.51 Million CAD | 4.79% |
| 2002 Q3 | 1.4 Million CAD | 81.55% |
| 2002 FY | 9.48 Million CAD | 25205.64% |
| 2002 Q4 | 9.48 Million CAD | 575.68% |
| 2002 Q1 | 319.15 Thousand CAD | 0.0% |
| 2002 Q2 | 773.4 Thousand CAD | 142.33% |
| 2001 FY | 37.49 Thousand CAD | -99.38% |
| 2000 FY | 6.03 Million CAD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Capstone Therapeutics Corp. | 20.32 Million USD | 54.392% |
| Skye Bioscience, Inc. | 4.61 Million USD | -100.881% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 68.854% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -7468.328% |
| Qrons Inc. | 351.84 Thousand USD | -2535.01% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | 5.87 Million USD | -57.913% |
| BioStem Technologies, Inc. | 4.71 Million USD | -96.782% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -1126.019% |
| CSL Limited | 12.18 Billion USD | 99.924% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 79.651% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 78.624% |
| Rebus Holdings, Inc. | 310 Thousand USD | -2890.71% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -1371.44% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -35948.066% |
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 77.499% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | -124.922% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -2207.136% |
| SQZ Biotechnologies Company | 27.47 Million USD | 66.251% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -298.598% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -877.695% |
| Mesoblast Limited | 118.7 Million USD | 92.189% |
| Marizyme, Inc. | 18.71 Million USD | 50.468% |
| Genus plc | 233.1 Million USD | 96.023% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -216.381% |
| Pharming Group N.V. | 171.54 Million USD | 94.595% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -943.979% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -590.035% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -1136.16% |
| ContraFect Corporation | 2.88 Million USD | -221.805% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -6742.872% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -541.021% |
| IMV Inc. | 28.88 Million USD | 67.902% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | -63.85% |
| MultiCell Technologies, Inc. | 202.58 USD | -4576463.333% |
| ONE Bio Corp. | 19.71 Million USD | 52.974% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 83.873% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.49 Million USD | -520.251% |
| Q BioMed Inc. | 4.1 Million USD | -125.578% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 71.991% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -654.762% |
| Biomind Labs Inc. | 735.54 Thousand USD | -1160.459% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 86.294% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | -206.365% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 28.667% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -2477.41% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -6451.253% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -310.524% |
| GB Sciences, Inc. | 1.75 Million USD | -426.98% |
| Alpha Cognition Inc. | 1.22 Million USD | -659.703% |
| HST Global, Inc. | 98.31 Thousand USD | -9329.716% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -3627.566% |
| Halberd Corporation | 150 Thousand USD | -6080.801% |
| Enzolytics Inc. | 996.33 Thousand USD | -830.528% |
| Agentix Corp. | 50 Thousand USD | -18442.404% |
| Resverlogix Corp. | 6.49 Million USD | -42.832% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -3527.344% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 20 Million USD | 53.644% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -31.082% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -242.275% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -90571.902% |
| Genscript Biotech Corporation | 417.73 Million USD | 97.781% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -4521.367% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -286.667% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -3943.422% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -6136.766% |
| Kadimastem Ltd | 891.22 Thousand USD | -940.275% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -3605.783% |
| LadRx Corporation | 33.6 Thousand USD | -27487.937% |
| Cell Source, Inc. | 9.25 Million USD | -0.184% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -1126.019% |
| NovAccess Global Inc. | 2.19 Million USD | -321.441% |
| Affymax, Inc. | - USD | -Infinity% |
| Itoco Inc. | 228.37 Thousand USD | -3959.604% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -4294.455% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | -86.057% |
| Mobile Lads Corp. | 484.28 Thousand USD | -1814.414% |
| CytoDyn Inc. | 30.07 Million USD | 69.174% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -18.558% |
| SYBLEU INC | 477.5 Thousand USD | -1841.613% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | -95.79% |
| International Stem Cell Corporation | 4.17 Million USD | -121.905% |
| Bioxytran, Inc. | 1.92 Million USD | -381.621% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -14754.601% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -325.109% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | -11.486% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | -7.993% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -496.035% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -3359.404% |
| Neutra Corp. | 54.15 Thousand USD | -17019.436% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -406.623% |
| PureTech Health plc | 25.51 Million USD | 63.659% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -657.311% |
| IXICO plc | 472.02 Thousand USD | -1864.142% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 40.19% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 85.11% |
| CSL Limited | 12.18 Billion USD | 99.924% |
| Cellectis S.A. | 92.77 Million USD | 90.007% |